From the Journals

Delays in cancer referral, diagnosis linked with morbidities


 

FROM FAMILY PRACTICE

People with multiple preexisting chronic conditions experience a longer wait to receive a diagnosis of cancer and are more likely to be referred to an emergency department for their cancer, according to new research.

These findings are based on a retrospective study of data from 11,716 cancer patients from the United Kingdom’s National Cancer Diagnosis Audit – an initiative that aimed to better understand the journey of cancer patients from primary care to diagnosis. Three-quarters of the study participants had at least one morbidity in their primary care record, according to the authors of the new research, which was published in Family Practice (2021 Nov 30. doi: 10.1093/fampra/cmab139).

In their analysis of all of the patient data, Minjoung M. Koo and colleagues found that the median time between first presenting to a primary care physician with cancer symptoms and being referred to a specialist was 5 days. For all patients studied, the median time to receiving a cancer diagnosis was 42 days, the investigators wrote.

Patients with multiple morbidities were 26% more likely to have their cancer diagnosed at least 60 days after the initial primary care consultation than were those without morbidities (95% confidence interval, 1.10-1.45). This was true after adjustment for confounders, including morbidity, sex, age, and cancer. Similarly, those with a Charlson score of 3 or above – signifying more severe comorbidities – had a 19% greater odds of being diagnosed more than 60 days after presenting to primary care (95% CI, 1.01-1.40)

Older adults ‘less likely to be screen-detected’

Dr. Fran Boyle, professor of medical oncology at the University of Sydney, Australia, said it wasn’t clear from the study whether people with multiple comorbidities may have symptoms that cloud the diagnostic process, or whether short primary care consultations may not allow for enough time to manage multiple issues.

“Older adults typically have more comorbidities, and they are less likely to be screen-detected; for example, breast cancer screening and bowel cancer screening typically stop after 75,” said Dr. Boyle, director of Patricia Ritchie Centre for Cancer Care and Research at Sydney’s Mater Hospital.

Dr. Boyle pointed to a recent systematic review in Australian rural oncology that suggested that patients with more comorbidities tend to be offered less intense treatment, and have higher operative mortality and morbidity, which can contribute to less effective therapy.

Referral delays seen in multiple patient groups

Ms. Koo, from the University College London and the National Disease Registration Service in the United Kingdom, and coauthors noted a nonsignificant trend toward increased intervals between primary care consultation and referral or diagnosis even in patients with one or more comorbidities.

A higher burden of comorbidities also meant patients were more likely to have more than one primary care consultation before being referred to a specialist. Those with three or more comorbidities were 21% more likely to have at least three consultations before referral, compared with patients with no comorbidities (95% CI, 1.05-1.40, P = .010).

Overall, 60% of the participants in the study experienced at least one investigation into whether they had cancer by a primary care clinician before being referred to a specialist.

Pages

Recommended Reading

FDA expands pembrolizumab approval for advanced melanoma
MDedge Hematology and Oncology
Metformin does not improve outcomes in early breast cancer
MDedge Hematology and Oncology
Vitamin D counters bone density loss with aromatase inhibitors
MDedge Hematology and Oncology
1 in 7 breast cancers are overdiagnosed
MDedge Hematology and Oncology
Ongoing HER2 breast cancer therapy may cost an additional $68,000 per patient
MDedge Hematology and Oncology
Genomic instability varies between breast cancer subtypes
MDedge Hematology and Oncology
Liver cancer risk lingers even after HCV eradication
MDedge Hematology and Oncology
Women struggle with benzodiazepine addiction post chemotherapy treatment
MDedge Hematology and Oncology
Omega-3 supplements may impact breast cancer risk
MDedge Hematology and Oncology
Antibiotic use associated with triple-negative breast cancer mortality
MDedge Hematology and Oncology